Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Net Margin (2022 - 2025)

Arcutis Biotherapeutics has reported Net Margin over the past 4 years, most recently at 13.84% for Q4 2025.

  • Quarterly results put Net Margin at 13.84% for Q4 2025, up 2939.0% from a year ago — trailing twelve months through Dec 2025 was 4.37% (up 6761.0% YoY), and the annual figure for FY2025 was 4.35%, up 7974.0%.
  • Net Margin for Q4 2025 was 13.84% at Arcutis Biotherapeutics, up from 7.47% in the prior quarter.
  • Over the last five years, Net Margin for ARQT hit a ceiling of 13.84% in Q4 2025 and a floor of 14856.41% in Q3 2022.
  • Median Net Margin over the past 4 years was 121.01% (2023), compared with a mean of 1611.62%.
  • Biggest five-year swings in Net Margin: surged 1470720bps in 2023 and later skyrocketed 2939bps in 2025.
  • Arcutis Biotherapeutics' Net Margin stood at 2432.25% in 2022, then skyrocketed by 80bps to 489.95% in 2023, then surged by 97bps to 15.55% in 2024, then surged by 189bps to 13.84% in 2025.
  • The last three reported values for Net Margin were 13.84% (Q4 2025), 7.47% (Q3 2025), and 19.49% (Q2 2025) per Business Quant data.